Research Papers:

Toll-like receptor 9 expression is associated with breast cancer sensitivity to the growth inhibitory effects of bisphosphonates in vitro and in vivo

Jouko Sandholm, Jaakko Lehtimäki, Tamiko Ishizu, Sadanandan E. Velu, Jeremy Clark, Pirkko Härkönen, Arja Jukkola-Vuorinen, Aleksi Schrey, Kevin W. Harris, Johanna M. Tuomela and Katri S. Selander _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:87373-87389. https://doi.org/10.18632/oncotarget.13570

Metrics: PDF 1614 views  |   HTML 2293 views  |   ?  


Jouko Sandholm1, Jaakko Lehtimäki2, Tamiko Ishizu2,3, Sadanandan E. Velu4, Jeremy Clark4, Pirkko Härkönen2, Arja Jukkola-Vuorinen5, Aleksi Schrey6, Kevin W. Harris7,8,9, Johanna M. Tuomela2, Katri S. Selander4,10

1Cell Imaging Core, Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland

2Department of Cell Biology and Anatomy, University of Turku, Turku, Finland

3MediCity Research Laboratory/PET, Turku PET Centre, University of Turku, Turku, Finland

4Department of Chemistry, University of Alabama at Birmingham, Birmingham, AL, U.S.A

5Oulu University Hospital, Department of Oncology, Oulu, Finland

6Department of Otorhinolaryngology – Head and Neck Surgery, Turku University Hospital, Turku, Finland

7Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, U.S.A

8Birmingham Veterans Affairs Medical Center, Birmingham, AL, U.S.A

9UAB Comprehensive Cancer Center, Birmingham, AL, U.S.A

10Department of Pathology, Lapland Central Hospital, Rovaniemi, Finland

Correspondence to:

Katri S. Selander, email: [email protected]

Keywords: breast cancer, bisphosphonate, biomarker, TLR9, ApppI

Received: March 05, 2016    Accepted: November 04, 2016    Published: November 24, 2016


Bisphosphonates are standard treatments for bone metastases. When given in the adjuvant setting, they reduce breast cancer mortality and recurrence in bone but only among post-menopausal patients. Optimal drug use would require biomarker-based patient selection. Such biomarkers are not yet in clinical use. Based on the similarities in inflammatory responses to bisphosphonates and Toll-like receptor (TLR) agonists, we hypothesized that TLR9 expression may affect bisphosphonate responses in cells. We compared bisphosphonate effects in breast cancer cell lines with low or high TLR9 expression. We discovered that cells with decreased TLR9 expression are significantly more sensitive to the growth-inhibitory effects of bisphosphonates in vitro and in vivo. Furthermore, cancer growth-promoting effects seen with some bisphosphonates in some control shRNA cells were not detected in TLR9 shRNA cells. These differences were not associated with inhibition of Rap1A prenylation or p38 phosphorylation, which are known markers for bisphosphonate activity. However, TLR9 shRNA cells exhibited increased sensitivity to ApppI, a metabolite that accumulates in cells after bisphosphonate treatment. We conclude that decreased TLR9-expression sensitizes breast cancer cells to the growth inhibitory effects of bisphosphonates. Our results suggest that TLR9 should be studied as a potential biomarker for adjuvant bisphosphonate sensitivity among breast cancer patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13570